Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo

Journal of Hepatology

Volumn 42, Issue 5, 2005, Pages 736-743

  Barraud, Luc ^a,b   Merle, Philippe ^a   Soma, Emilienne ^b   Lefrançois, Lydie ^a   Guerret, Sylviane ^c   Chevallier, Michèle ^d   Dubernet, Catherine ^e   Couvreur, Patrick ^e   Trépo, Christian ^a   Vitvitski, Ludmila ^a  

^a INSERM   (France)

^b BioAlliance Pharma   (France)

^c NOVOTEC   (France)

^d LMM Laboratoire Marcel Merieux   (France)

^e UNIV PARIS SUD   (France)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Multidrug resistance; Nanoparticles; Transgenic mice

Indexed keywords

CYANOACRYLATE DERIVATIVE; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 3; NANOPARTICLE; POLYISOHEXYLCYANOACRYLATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER MODEL; CARCINOMA CELL; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; MULTIDRUG RESISTANCE; NICK END LABELING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE;

EID: 20144389123     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.12.035     Document Type: Article

References (40)

1. K. Ikeda, S. Saitoh, I. Koida, Y. Arase, A. Tsubota, and K. Chayama A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis Hepatology 18 1993 47 53
2. H.B. El-Serag, and A.C. Mason Rising incidence of hepatocellular carcinoma in the United States N Engl J Med 340 1999 745 750
3. J.M. Llovet, M.I. Real, X. Montana, R. Planas, S. Coll, and J. Aponte Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
4. C.L. Lai, P.C. Wu, G.C. Chan, A.S. Lok, and H.J. Lin Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial Cancer 62 1988 479 483
5. R. Krishna, and L.D. Mayer Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Eur J Pharm Sci 11 2000 265 283
6. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1999 361 398
7. J.J. Bao, B.P. Lee, L.C. Stephens, A.A. Sahin, N.T. Van, and D.A. Johnston Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein Mol Carcinog 29 2000 103 111
8. J.G. Park, S.K. Lee, I.G. Hong, H.S. Kim, K.H. Lim, and K.J. Choe MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines J Natl Cancer Inst 86 1994 700 705
9. M. Itsubo, T. Ishikawa, G. Toda, and M. Tanaka Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma Cancer 73 1994 298 303
10. I.O. Ng, C.L. Liu, S.T. Fan, and M. Ng Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response Am J Clin Pathol 113 2000 355 363
11. Y.Y. Chou, A.L. Cheng, and H.C. Hsu Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation J Gastroenterol Hepatol 12 1997 569 575
12. Y. Soini, N. Virkajarvi, H. Raunio, and P. Paakko Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis J Clin Pathol 49 1996 470 473
13. G.J. Zaman, M.J. Flens, M.R. van Leusden, M. de Haas, H.S. Mulder, and J. Lankelma The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump Proc Natl Acad Sci USA 91 1994 8822 8826
14. H. Tapiero, Z. Mishal, M. Wioland, A. Silber, A. Fourcade, and G. Zwingelstein Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin Anticancer Res 6 1986 649 652
15. J.A. Kellen The reversal of multidrug resistance in cancer (review) Anticancer Res 13 1993 959 961
16. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv Drug Deliv Rev 54 2002 631 651
17. L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampeneere, and P. Speiser Pharmacokinetics and distribution of a biodegradable drug-carrier Int J Pharm 15 1993 335 345
18. C. Chavany, T. Saison-Behmoaras, T. Le Doan, F. Puisieux, P. Couvreur, and C. Helene Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake Pharm Res 11 1994 1370 1378
19. P. Couvreur, P. Tulkens, M. Roland, A. Trouet, and P. Speiser Nanocapsules: a new type of lysosomotropic carrier Fed Eur Biochem Soc Lett 84 1977 323 326
20. S. Bennis, C. Chapey, P. Couvreur, and J. Robert Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture Eur J Cancer 1 1994 89 93
21. A.C. Colin de Verdiere, C. Dubernet, F. Nemati, E. Soma, M. Appel, and J. Ferte Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action Br J Cancer 76 1997 198 205
22. C. Cuvier, L. Roblot-Treupel, J.M. Millot, G. Lizard, S. Chevillard, and M. Manfait Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance Biochem Pharmacol 44 1992 509 517
23. A. Colin de Verdiere, C. Dubernet, F. Nemati, M.F. Poupon, F. Puisieux, and P. Couvreur Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells Cancer Chemother Pharmacol 33 1994 504 508
24. O. Terradillos, O. Billet, C.A. Renard, R. Levy, T. Molina, and P. Briand The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice Oncogene 14 1997 395 404
25. P. Merle, L. Barraud, L. Lefrancois, M. Chevallier, S. Guerret, and M. Maisonnas Long-term high-dose interferon-alpha therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice Oncogene 22 2003 2762 2771
26. C.E. Soma, C. Dubernet, G. Barratt, S. Benita, and P. Couvreur Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro J Control Release 68 2000 283 289
27. P. Gripon, S. Rumin, S. Urban, J. Le Seyec, D. Glaise, and I. Cannie Infection of a human hepatoma cell line by hepatitis B virus Proc Natl Acad Sci USA 99 2002 15655 15660
28. R. Fautz, B. Husein, and C. Hechenberger Application of the neutral red assay (NR assay) to monolayer cultures of primary hepatocytes: rapid colorimetric viability determination for the unscheduled DNA synthesis test (UDS) Mutat Res 253 1991 173 179
29. S.E. Dunn, and J.M. Cullen Woodchuck p-glycoprotein found in virus-induced hepatocellular carcinomas binds anticancer drugs Cancer Lett 110 1996 177 180
30. M.T. Kuo, J.Y. Zhao, L.D. Teeter, M. Ikeguchi, and F.V. Chisari Activation of multidrug resistance (P-glycoprotein) mdr3/mdr1a gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice Cell Growth Differ 3 1992 531 540
31. N. Chiannilkulchai, Z. Driouich, J.P. Benoit, A.L. Parodi, and P. Couvreur Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases Sel Cancer Ther 5 1989 1 11
32. N. Chiannilkulchai, N. Ammoury, B. Caillou, J.P. Devissaguet, and P. Couvreur Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice Cancer Chemother Pharmacol 26 1990 122 126
33. M.A. Sells, M.L. Chen, and G. Acs Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA Proc Natl Acad Sci USA 84 1987 1005 1009
34. S.L. Doong, M.H. Lin, M.M. Tsai, T.R. Li, S.E. Chuang, and A.L. Cheng Transactivation of the human MDR1 gene by hepatitis B virus X gene product J Hepatol 29 1998 872 878
35. S.W. Lowe, S. Bodis, A. McClatchey, L. Remington, H.E. Ruley, and D.E. Fisher p53 Status and the efficacy of cancer therapy in vivo Science 266 1994 807 810
36. J. Mordenti Dosage regimen design for pharmaceutical studies conducted in animals J Pharm Sci 75 1986 852 857
37. J. Mordenti Man versus beast: pharmacokinetic scaling in mammals J Pharm Sci 75 1986 1028 1040
38. C. Verdun, F. Brasseur, H. Vranckx, P. Couvreur, and M. Roland Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles Cancer Chemother Pharmacol 26 1990 13 18
39. D. Wein, and S. Gupta Expression of P-glycoprotein, encoded by MDR 1 gene, a metabolically active efflux pump in murine mast cells Cancer Lett 101 1996 241 246
40. C.A. Slapak, P.M. Fracasso, R.L. Martell, D.L. Toppmeyer, J.M. Lecerf, and S.B. Levy Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells Cancer Res 54 1994 5607 5613